Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.63 |
| ▸ | RAF1 | P04049 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CDK8 | P49336 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101332 | 0.92 | RAF1 (0.63) | NAMPTRAF1RAB9ACDK8CA1 | |
| SCHEMBL101750 | 0.91 | RET (0.57) | NAMPTRAF1CDK8CA1CA2 | |
| SCHEMBL171340 | 0.86 | NAMPT (0.60) | NAMPTRAF1RAB9ACDK8NPC1 | |
| SCHEMBL1790844 | 0.86 | NAMPT (0.66) | NAMPTRAB9ANPC1CA1CA2 | |
| SCHEMBL16628062 | 0.84 | RAF1 (0.76) | RAF1CDK8CA7CA9RET | |
| SCHEMBL5636194 | 0.84 | RAF1 (0.64) | RAF1CDK8CA1CA2CA7 | |
| SCHEMBL6031235 | 0.83 | RAF1 (0.66) | RAF1RAB9ACDK8CA1CA2 | |
| SCHEMBL13603756 | 0.81 | NAMPT (0.73) | NAMPTNPC1SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL1790568 | 0.81 | NAMPT (0.65) | NAMPTRAB9ANPC1CA1CA2 | |
| SCHEMBL13648230 | 0.81 | RAF1 (0.66) | RAF1CDK8CA7CA9RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20060199844-A1 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1562905-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004037789-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | NAMPT 1163/4885RAF1 2/4885RAB9A 2000/4885 |
| US-20060199844-A1 | Methylene urea derivatives | BRAF, RAF1, CMPK1 | NAMPT 1163/4885RAF1 2/4885RAB9A 2000/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | NAMPT 1163/4885RAF1 2/4885RAB9A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.